Sign in
CGEM Stock Price, Chart, Stats & News
Cullinan Therapeutics, Inc.
Save
935.38M
Market cap
–
Current P/E
6.74x
Forward P/E
CGEM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.04% |
ROE | -46.19% |
D/E | 0.01x |
Interest coverage ratio | – |
CGEM valuation
P/E | – |
P/S | – |
P/B | 1.86x |
P/CF | -4.33x |
P/FCF | -5.60x |
P/OCF | -4.33x |
PEG | 2.55x |
EV multiple | -3.57x |
About
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617.
Similar securities
Based on sector and market capitalization
Report issue